Strategic partnerships DDI is embedded in The Ohio State University Comprehensive Cancer Center and actively partners with pharmaceutical, biotech, and venture capital firms to bridge discovery and early clinical development, presenting opportunities to co-develop or fund early-stage oncology programs.

Clinical translation focus The institute emphasizes rapid translation of university cancer research into clinical-stage candidates, creating a potential sales angle for contract development, regulatory support, and early-phase trial services.

Small but nimble With a compact team (2-10 employees) and a focus on high-value programs, DDI may seek scalable external services, enabling outsized impact from targeted CRO partnerships, specialized analytics, and modular drug development resources.

Funding and growth Reported revenue in the range of 1M to 10M signals room for strategic collaborations, licensing deals, or sponsored research arrangements with larger firms seeking early access to OSU innovations and pipeline opportunities.

Academic access and expertise DDI leverages world-class OSU research and an internationally recognized advisory board, offering a pathway for sales conversations around access to novel targets, preclinical data, and expert advisory services to de-risk early development.